Becker Muscular Dystrophy Clinical Trial
Official title:
An Open-label Pilot Study of Purified Tea-derived Epicatechin to Improve Mitochondrial Function, Strength and Skeletal Muscle Exercise Response in Becker Muscular Dystrophy.
(-)-Epicatechin will be evaluated for the treatment of progressive muscle loss and impaired skeletal muscle function in Becker Muscular Dystrophy (BMD) patients.
This is a proof-of-concept phase 1/2a pilot and endpoint development study that is designed to provide initial evidence of biological activity of (-)-epicatechin. Primary endpoints include initial assessment of tissue-specific evidence of efficacy from muscle biopsy samples. Secondary endpoints include measures of strength and physical function, and safety and adverse event data. Pilot endpoints include assessment of mRNA and miRNA peripheral blood profiles and validation of non-invasive near-infrared spectroscopy (NIRS) muscle perfusion studies during exercise and a recumbent cycle exercise test that may be employed as endpoints in future clinical trials. This single center open-label pilot study will enroll 10 adults with genetically-confirmed Becker muscular dystrophy, who will receive the purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks. After screening visits, participants will be enrolled in the study if they meet all inclusion criteria. They will be evaluated at baseline and at screening, day 1, and weeks 1, 2, 4 and 8. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01168908 -
Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy
|
Phase 2 | |
| Recruiting |
NCT01484678 -
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
|
||
| Completed |
NCT02147639 -
Effects of Sodium Nitrate on Blood Flow in Becker Muscular Dystrophy
|
Phase 2/Phase 3 | |
| Completed |
NCT02847975 -
Sodium Nitrate to Improve Blood Flow
|
Phase 1 | |
| Recruiting |
NCT02069756 -
The Duchenne Registry
|
||
| Completed |
NCT04585464 -
A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults
|
Phase 1 | |
| Recruiting |
NCT04668716 -
Brain Involvement in Dystrophinopathies Part 2
|
||
| Completed |
NCT03236662 -
(-)- Epicatechin Becker Muscular Dystrophy
|
Phase 2 | |
| Completed |
NCT01350154 -
Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients
|
Phase 2 | |
| Enrolling by invitation |
NCT06066580 -
Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
|
Phase 2 | |
| Not yet recruiting |
NCT06363526 -
Effectiveness of 5-week Digital Respiratory Practice in a Group of Children With Duchenne Muscular Dystrophy and Becker Muscular Dystrophy.
|
N/A | |
| Recruiting |
NCT05409079 -
Schulze Muscular Dystrophy Ability Clinical Study
|
N/A | |
| Completed |
NCT01557400 -
Study of Ataluren for Previously Treated Participants With Nonsense Mutation Duchenne/Becker Muscular Dystrophy (nmDBMD) in Europe, Israel, Australia, and Canada
|
Phase 3 | |
| Recruiting |
NCT02109692 -
Evaluation of Muscle miRNA as Biomarkers in Dystrophinopathies
|
N/A | |
| Recruiting |
NCT03057002 -
UTSW HP [13-C] Pyruvate Injection in HCM
|
||
| Recruiting |
NCT04583917 -
Brain Involvement in Dystrophinopathies Part 1
|
||
| Completed |
NCT02207283 -
PDE5 Inhibition to Alleviate Functional Muscle Ischemia in Becker Muscular Dystrophy
|
Phase 4 | |
| Withdrawn |
NCT03076814 -
Functional Muscle Ischemia With Tadalafil Treatment in Becker Muscular Dystrophy
|
N/A | |
| Completed |
NCT00873782 -
Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy
|
Phase 1 | |
| Not yet recruiting |
NCT05715957 -
Follow-up Study on Female Carriers With DMD Gene Variants
|